Nangaku M[au] - Search Results

Year	Number of Results
1990	3
1991	2
1992	1
1994	1
1995	1
1996	4
1997	7
1998	8
1999	6
2000	1
2001	7
2002	14
2003	13
2004	16
2005	18
2006	15
2007	23
2008	22
2009	8
2010	12
2011	10
2012	14
2013	31
2014	42
2015	37
2016	30
2017	35
2018	42
2019	65
2020	86
2021	42

1

Pathogenesis of Atypical Hemolytic Uremic Syndrome.

Yoshida Y, Kato H, Ikeda Y, Nangaku M. Yoshida Y, et al. Among authors: nangaku m. J Atheroscler Thromb. 2019 Feb 1;26(2):99-110. doi: 10.5551/jat.RV17026. Epub 2018 Nov 2. J Atheroscler Thromb. 2019. PMID: 30393246 Free PMC article. Review.

2

Mitochondrial Damage Causes Inflammation via cGAS-STING Signaling in Acute Kidney Injury.

Maekawa H, Inoue T, Ouchi H, Jao TM, Inoue R, Nishi H, Fujii R, Ishidate F, Tanaka T, Tanaka Y, Hirokawa N, Nangaku M, Inagi R. Maekawa H, et al. Among authors: nangaku m. Cell Rep. 2019 Oct 29;29(5):1261-1273.e6. doi: 10.1016/j.celrep.2019.09.050. Cell Rep. 2019. PMID: 31665638 Free article.

3

COVID-19 of dialysis patients in Japan: Current status and guidance on preventive measures.

COVID-19 Task Force Committee of the Japanese Association of Dialysis Physicians; Japanese Society for Dialysis Therapy; Japanese Society of Nephrology, Kikuchi K, Nangaku M, Ryuzaki M, Yamakawa T, Hanafusa N, Sakai K, Kanno Y, Ando R, Shinoda T, Nakamoto H, Akizawa T. COVID-19 Task Force Committee of the Japanese Association of Dialysis Physicians, et al. Among authors: nangaku m. Ther Apher Dial. 2020 Aug;24(4):361-365. doi: 10.1111/1744-9987.13531. Ther Apher Dial. 2020. PMID: 32506762 Free PMC article. Review.

4

More reasons to use SGLT2 inhibitors: EMPEROR-reduced and DAPA-CKD.

Nangaku M. Nangaku M. Kidney Int. 2020 Dec;98(6):1387-1389. doi: 10.1016/j.kint.2020.10.002. Epub 2020 Oct 14. Kidney Int. 2020. PMID: 33068607 No abstract available.

5

Recommendations by the Asian Pacific society of nephrology (APSN) on the appropriate use of HIF-PH inhibitors.

Yap DYH, McMahon LP, Hao CM, Hu N, Okada H, Suzuki Y, Kim SG, Lim SK, Vareesangthip K, Hung CC, Nangaku M; APSN HIF-PHI Recommendation Committee. Yap DYH, et al. Among authors: nangaku m. Nephrology (Carlton). 2021 Feb;26(2):105-118. doi: 10.1111/nep.13835. Epub 2020 Dec 9. Nephrology (Carlton). 2021. PMID: 33222343 Free PMC article. Review.

6

Efficacy and Safety of Daprodustat Compared with Darbepoetin Alfa in Japanese Hemodialysis Patients with Anemia: A Randomized, Double-Blind, Phase 3 Trial.

Akizawa T, Nangaku M, Yonekawa T, Okuda N, Kawamatsu S, Onoue T, Endo Y, Hara K, Cobitz AR. Akizawa T, et al. Among authors: nangaku m. Clin J Am Soc Nephrol. 2020 Aug 7;15(8):1155-1165. doi: 10.2215/CJN.16011219. Epub 2020 Jul 28. Clin J Am Soc Nephrol. 2020. PMID: 32723804

7

Hypoxia-Inducible Factor-Prolyl Hydroxylase Domain Inhibitors to Treat Anemia in Chronic Kidney Disease.

Sakashita M, Tanaka T, Nangaku M. Sakashita M, et al. Among authors: nangaku m. Contrib Nephrol. 2019;198:112-123. doi: 10.1159/000496531. Epub 2019 Apr 16. Contrib Nephrol. 2019. PMID: 30991411 Review.

8

A 24-Week Anemia Correction Study of Daprodustat in Japanese Dialysis Patients.

Tsubakihara Y, Akizawa T, Nangaku M, Onoue T, Yonekawa T, Matsushita H, Endo Y, Cobitz A. Tsubakihara Y, et al. Among authors: nangaku m. Ther Apher Dial. 2020 Apr;24(2):108-114. doi: 10.1111/1744-9987.12962. Epub 2019 Aug 13. Ther Apher Dial. 2020. PMID: 31306555 Clinical Trial.

9

Global case studies for chronic kidney disease/end-stage kidney disease care.

Yang CW, Harris DCH, Luyckx VA, Nangaku M, Hou FF, Garcia Garcia G, Abu-Aisha H, Niang A, Sola L, Bunnag S, Eiam-Ong S, Tungsanga K, Richards M, Richards N, Goh BL, Dreyer G, Evans R, Mzingajira H, Twahir A, McCulloch MI, Ahn C, Osafo C, Hsu HH, Barnieh L, Donner JA, Tonelli M. Yang CW, et al. Among authors: nangaku m. Kidney Int Suppl (2011). 2020 Mar;10(1):e24-e48. doi: 10.1016/j.kisu.2019.11.010. Epub 2020 Feb 19. Kidney Int Suppl (2011). 2020. PMID: 32149007 Free PMC article. Review.

10

The oral hypoxia-inducible factor prolyl hydroxylase inhibitor enarodustat counteracts alterations in renal energy metabolism in the early stages of diabetic kidney disease.

Hasegawa S, Tanaka T, Saito T, Fukui K, Wakashima T, Susaki EA, Ueda HR, Nangaku M. Hasegawa S, et al. Among authors: nangaku m. Kidney Int. 2020 May;97(5):934-950. doi: 10.1016/j.kint.2019.12.007. Epub 2019 Dec 25. Kidney Int. 2020. PMID: 32171449 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results